FDA Approves Nexavar for Patients with Inoperable Liver Cancer The
FDA Approves Nexavar for Patients with Inoperable Liver Cancer
The U.S. Food and Drug Administration today approved Nexavar (sorafenib) for use in patients with a form of liver cancer known as hepatocellular carcinoma, when the cancer is inoperable. Nexavar was originally approved in 2005 for the treatment of patients with advanced renal cell carcinoma, a form of kidney cancer.